Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Dietrich, Dimo ^a   Jung, Maria ^a   Puetzer, Svenja ^a   Leisse, Annette ^a   Holmes, Emily Eva ^a   Meller, Sebastian ^a   Uhl, Barbara ^a   Schatz, Philipp ^b   Ivascu, Claudia ^c   Kristiansen, Glen ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Metanomics Health GmbH   (Germany)

^c ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SEPTINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84893547259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084225     Document Type: Article

References (42)

1. Marel M, Stastny B, Melínová L, Svandová E, Light RW (1995) Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest 107: 1598-1603.
2. Porcel JM, Light RW (2013) Pleural effusions. Dis Mon 59: 29-57.
3. Bhatnagar R, Maskell NA (2013) Treatment of complicated pleural effusions in 2013. Clin Chest Med 34: 47-62.
4. Mitrouska I, Klimathianaki M, Siafakas NM. (2005) Effects of pleural effusion on respiratory function. Can Respir J. 11: 499-503.
5. Heffner JE. (2008) Diagnosis and management of malignant pleural effusions.- .Respirology.13: 5-20.
6. Leuallen EC, Carr DT. (1955) Pleural effusion; a statistical study of 436 patients. N Engl J Med. 252: 79-83.
7. DiBonito L, Falconieri G, Colautti I, Bonifacio D, Dudine S (1992) The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol 36: 329-332.
8. Heffner JE, Nietert PJ, Barbieri C (2000) Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 117: 79-86. (Pubitemid 30053624)
9. Gonzalez AV, Bezwada V, Beamis JF Jr, Villanueva AG (2010) Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest 137: 1375-1381.
10. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ (2010) BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 65 Suppl 2: ii32-40.
11. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, et al. (2001) Management of malignant pleural effusions. Eur Respir J 18: 402-419. (Pubitemid 32776419)
12. Woenckhaus M, Grepmeier U, Werner B, Schulz C, Rockmann F et al. (2005) Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology. J Mol Diagn 7: 517-524. (Pubitemid 41479718)
13. Brock MV, Hooker CM, Yung R, Guo M, Han Y et al. (2005) Can we improve the cytologic examination of malignant pleural effusions using molecular analysis? Ann Thorac Surg 80: 1241-1247. (Pubitemid 41354096)
14. Jay SJ (1985) Diagnostic procedures for pleural disease. Clin Chest Med 6: 33-48.
15. Maskell NA, Butland RJ (2003) BTS guidelines for the investigation of a unilateral pleural effusion in adults. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. Thorax. 58 Suppl 2: ii8-17.
16. Rodríguez-Panadero F (2008) Medical thoracoscopy. Respiration. 76: 363-372.
17. Alataş F, Alataş O, Metintaş M, Colak O, Harmanci E el al. (2001) Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 31: 9-16. (Pubitemid 32012598)
18. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, et al. (2008) Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 63: 35-41.
19. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B (2004). Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 126: 1757-1763. (Pubitemid 39643976)
20. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484-492.
21. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11: 726-734.
22. Shen H, Laird PW (2013) Interplay between the cancer genome and epigenome. Cell 153: 38-55.
23. Suvà ML, Riggi N, Bernstein BE (2013) Epigenetic reprogramming in cancer. Science 339: 1567-1570.
24. Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G et al.(2012) DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol 21: 93-104.
25. Schneider KU, Dietrich D, Fleischhacker M, Leschber G, Merk J et al. (2011) Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer. 11: 102.
26. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C et al. (2010) SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10:600.
27. Dietrich D, Kneip C, Raji O, Liloglou T, Seegebarth A et al. (2012) Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 40: 825-832.
28. Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M et al. (2011) SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 6: 1632-1638.
29. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J et al. (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54: 414-423. (Pubitemid 351302625)
30. Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM et al (2008). Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3: e3759.
31. deVos T, Tetzner R, Model F, Weiss G, Schuster M, et al. (2009) Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55: 1337-1346.
32. Tänzer M, Balluff B, Distler J, Hale K, Leodolter A et al. (2010) Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 5: e9061
33. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M et al. (2013) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. doi:10.1136/gutjnl-2012-304149
34. Heichman KA, Warren JD (2012) DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 50: 1707-1721.
35. Bennett KL, Karpenko M, Lin MT, Claus R, Arab K et al. (2008) Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 68: 4494-4499.
36. Kneip C, Schmidt B, Fleischhacker M, Seegebarth A, Lewin J et al. (2009) A novel method for sensitive and specific detection of DNA methylation biomarkers based on DNA restriction during PCR cycling. Biotechniques 47: 737-744.
37. Lewin J. (2011) Methods for preservation of genomic DNA sequence complexity. United States Patent Application 20110027789.
38. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826. (Pubitemid 26296693)
39. -1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist. 10: 501-507.
40. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, et al. (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 85: 265-272. (Pubitemid 350265805)
41. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, et al. (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 173:1155-1160. (Pubitemid 43726897)
42. Park DS, Hwang KE, Shim H, Kim BR, Choi KH, et al. (2012) Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions. Clin Exp Metastasis. 29:83-89.